Breast Cancer Liquid Biopsy Market Size Projected to Garner USD 2,495 Million by 2032 growing at 22.5% CAGR - Exclusive Report by Acumen Research and Consulting

Author: Acumen Research and Consulting

The Global Breast Cancer Liquid Biopsy Market Size is predicted to reach USD 2,495 Million by 2032 from USD 335 Million in 2022, at a CAGR of 22.5% between 2023 and 2032, as per the Acumen Research and Consulting

The market for breast cancer liquid biopsy is growing rapidly due to the increasing prevalence of breast cancer worldwide and the rising demand for non-invasive cancer diagnostic tools. Breast cancer liquid biopsy is a non-invasive diagnostic test that analyzes the DNA or RNA circulating in the blood to detect the presence of cancerous cells or cancer-related mutations. This diagnostic tool is gaining popularity as an alternative to traditional tissue biopsies because it is less invasive, less painful, and less expensive. Liquid biopsy can also help physicians to monitor disease progression, evaluate treatment response, and detect relapse in breast cancer patients.

The breast cancer liquid biopsy market is poised for significant growth in the upcoming years, fueled by various factors. Primarily, the mounting incidence of breast cancer is propelling the need for precise and effective diagnostic tools. As per the American Cancer Society, breast cancer ranks second in the list of most prevalent cancers among women globally, with an estimated 2.3 million new cases in 2020. Secondly, technological advancements have led to the development of highly sensitive and specific liquid biopsy assays capable of detecting cancerous cells or DNA mutations with greater accuracy. Lastly, the increasing awareness about the advantages of early cancer detection and personalized medicine is spurring the adoption of liquid biopsy tests among patients and healthcare providers.

Breast Cancer Liquid Biopsy Market Analysis

Breast Cancer Liquid Biopsy Market Statistics                           

  • Global breast cancer liquid biopsy market value was worth USD 335 Million in 2022, with a 22.5% CAGR from 2023 to 2032
  • North America breast cancer liquid biopsy market share occupied around 35% in 2022
  • Asia Pacific region is expected to expand at the highest CAGR between 2023 and 2032
  • By circulating biomarkers, the circulating cell-free DNA (cfDNA) segment captured the majority of the market
  • Rising demand for non-invasive diagnostic tools, propel the breast cancer liquid biopsy market revenue

Request for a sample of this premium research report@

Breast Cancer Liquid Biopsy Market Trends                  

The breast cancer liquid biopsy market is entering a new era of growth and evolution as researchers and companies continue to refine and expand the capabilities of these diagnostic tests. One key area of development is the use of liquid biopsy to guide treatment decisions and monitor disease progression. As more targeted therapies become available for breast cancer, liquid biopsy can help identify specific genetic mutations or alterations in cancer cells that can be targeted with these treatments.

Another area of evolution in the breast cancer liquid biopsy market is the development of multi-analyte tests that can detect multiple types of genetic alterations or cancer-related biomarkers in a single blood sample. This approach has the potential to increase the sensitivity and specificity of liquid biopsy tests, as well as provide more comprehensive information about the biology of a patient's cancer.

In addition to clinical applications, the breast cancer liquid biopsy market is also seeing growth in research and drug development. Liquid biopsy can be used to identify and enroll patients in clinical trials, monitor treatment response, and identify potential drug targets or biomarkers of drug resistance. As more companies and researchers invest in liquid biopsy research, the potential applications and impact of these tests are likely to continue to grow.

Breast Cancer Liquid Biopsy Market Segmentation                   

Acumen Research and Consulting has segmented the global breast cancer liquid biopsy market by circulating biomarkers, application, and region.

  • By circulating biomarkers, the industry is categorized into circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating cell-free DNA (cfDNA), and others.
  • By application, the market is divided into early detection/screening, treatment selection, diagnosis, and monitoring.
  • By region, the market is classified into Asia-Pacific, Latin America, North America, Europe, and the MEA.

Breast Cancer Liquid Biopsy Market Regional Overview          

According to the breast cancer liquid biopsy industry analysis, the Asia-Pacific region is currently the fastest-growing region in the market. This can be attributed to various factors, including a rise in the number of breast cancer cases in the region and increasing awareness about the benefits of liquid biopsy as a non-invasive and accurate diagnostic tool. In addition, the Asia-Pacific region has witnessed a significant increase in healthcare spending and infrastructure development in recent years, which has led to the availability of advanced liquid biopsy tests and technology. This has encouraged the adoption of liquid biopsy for breast cancer diagnosis and monitoring by healthcare professionals in the region. Moreover, the Asia-Pacific region is home to several emerging economies, which have a large patient pool and a growing demand for affordable and effective diagnostic tools. Liquid biopsy offers an attractive alternative to traditional biopsy methods, which are invasive and can be expensive. As a result, the breast cancer liquid biopsy market is expected to continue to grow in the Asia-Pacific region in the coming years.

Breast Cancer Liquid Biopsy Market Players                                          

Some of the prominent breast cancer liquid biopsy market companies are Guardant Health, Inc., Freenome Holdings, Inc., Biocept, Inc., Illumina, Inc., GRAIL, Inc., Qiagen N.V., Roche Holding AG, Thermo Fisher Scientific Inc., Exact Sciences Corporation, and Natera, Inc.

Click here to buy the Premium Market Research report

Receive our personalized services and customization by clicking here

Mr. Frank Wilson

Acumen Research and Consulting

USA: +13474743864

India: +918983225533